2018-04-16 (91 Days Old)Total Views: 20 | Last 7 Days: 0
(Reuters) - Merck & Co's immunotherapy Keytruda plus chemotherapy significantly improved overall survival versus chemotherapy alone in newly-diagnosed patients with advanced non-small cell lung cancer in a highly-anticipated study that appears to cement the company's lead in the most lucrative oncology market.
CNBC: Trump reinforces confidence in 'my intelligence people'
CNBC: Netflix tanks after huge subscriber miss
CNBC: Amazon cloud hits snags after Amazon Prime Day downtime
NBC New York: Renovations Keep Long Island Pool Closed
Reuters: Trump on Twitter (July 16): NATO, Russian Meddling
Reuters: Bank of America profit beats on consumer loan growth, lower expenses
WashingtonPost: Trump repudiates U.S. intelligence community by according equal weight to Putin
WashingtonPost: We just watched a U.S. president acting on behalf of a hostile power
WashingtonPost: Trump replaces national pride with personal vanity
FOX: The Latest: Spokesman says officers can conduct pat downs.
CNN: GOP lawmaker: Trump manipulated by Russian intel
CNN: Government shuts down website for doctors searching for treatment guidelines
CNN: Trump clashes with intelligence chief over Russian threat
CBS: Amazon Prime deals: What to avoid, what to buy
CBS: Johnny Depp settles $25M lawsuit against former managers
BBC: Amazon suffers web outages on Prime Day
ABC: Police unaware of man before college student's death
Los Angeles Times: Zsa Zsa Gabor’s former lavish Bel-Air estate returns with a major price markup
Daily Mail: Video: Toddler takes her first steps outside after lung transplant
Daily Mail: Reports: Spurs add F Cunningham
Daily Mail: Venezuela pleads guilty in U.S. to role in PDVSA bribe...
Daily Mail: Report: NFL teams' rev share topped $8B in '17
Daily Mail: Robin Goodfellow's racing tips: Best bets for Tuesday, July 17